Rtw Investments Adds $296M in CG Oncology, Inc. ($CGON)

RTW Investments has significantly increased its stake in CG Oncology, Inc. (NasdaqGS: CGON). According to a Form 13F filing with the SEC, RTW added 4,972,681 shares during the reporting period, boosting its total holdings by 247.1% to 6,984,808 shares. The value of the position is now approximately $416.02 million.

What Changed in RTW Investments' CG Oncology Position

RTW Investments' recent filing shows a strong vote of confidence in CG Oncology. The fund's previous stake was 2,012,127 shares, and the latest addition of nearly 5 million shares marks a substantial increase. The total value of RTW's holdings in CG Oncology now stands at $416.02 million, reflecting the fund's bullish stance.

Other Institutional Activity in CG Oncology

Several other funds also adjusted their positions in CG Oncology. T. Rowe Price Investment Management, Inc. added 6,297,797 shares, raising its total to 6,720,389 shares worth about $454.84 million. Decheng Capital LLC maintained its position with 6,371,669 shares valued at $431.23 million. Wellington Management Group LLP reduced its stake by 628,558 shares, ending with 5,371,232 shares valued at $363.52 million. BlackRock, Inc. added 220,938 shares, bringing its total to 5,064,180 shares worth approximately $342.74 million.

CG Oncology Stock Snapshot

Shares of CG Oncology (NasdaqGS: CGON) recently traded around $59.56. The company has a market cap of $5.25 billion and a forward P/E ratio that isn't meaningful as the company isn't profitable. The stock's 52-week range is between $23.65 and $75.50, with a 50-day moving average of $65.09 and a 200-day moving average of $51.20. CG Oncology maintains strong liquidity with a current ratio of 31.30 and a quick ratio of 30.60, alongside a debt-to-equity ratio of 0.69.

Recent Earnings

CG Oncology reported revenue of $5.07 million with a growth rate of 19.8%. Despite this, the company has a negative return on equity of -20.79% and no net margin, indicating ongoing challenges in achieving profitability. The next earnings report is expected on August 7, 2026.

Insider Buying and Selling at CG Oncology, Inc.

Recent insider activity at CG Oncology includes several purchases. On June 4, 2026, Christina Rossi, Victor Edward Jr. Tong, Susan Graf, Brian Guan-Chyun Liu, and James Mulay each bought 9,354 shares. These transactions were not part of any pre-planned trading programs.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on CG Oncology. On May 14, 2026, Truist Securities reiterated its 'buy' rating with a price target of $82. JP Morgan maintained its 'buy' rating with a $96 target on May 11, while RBC Capital also stuck with a 'buy' at $81. The consensus among 14 analysts is a 'buy' rating, with a mean price target of $90.29.

About CG Oncology

CG Oncology, Inc. is a biotechnology company based in Dallas, Texas. It focuses on developing therapies for bladder cancer, particularly through its investigational oncolytic immunotherapy, cretostimogene grenadenorepvec. The company is engaged in multiple clinical trials, including phase 2 and phase 3 studies, to assess the efficacy and safety of its treatments for various stages of bladder cancer. Founded in 2010, CG Oncology is led by CEO Arthur Kuan and employs about 142 people.

Bottom Line

RTW Investments' increased stake in CG Oncology suggests confidence in the company's future prospects, as reflected in the latest 13F filing. While CG Oncology faces challenges in profitability, its innovative approach in the biotechnology sector continues to attract institutional interest. Investors watch these filings closely for insights into institutional sentiment, though they reflect past positions and not necessarily current holdings.